STEVANATO GROUP SPA (STVN) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:STVN - IT0005452658 - Common Stock
STVN Key Statistics, Chart & Performance
The current stock price of STVN is 23.43 USD. In the past month the price decreased by -9.82%. In the past year, price increased by 16.97%.
STVN Latest News, Press Relases and Analysis
STVN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 26.16 | 221.31B | ||
| DHR | DANAHER CORP | 29.44 | 162.53B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 181.97 | 55.22B | ||
| A | AGILENT TECHNOLOGIES INC | 28.18 | 43.55B | ||
| IQV | IQVIA HOLDINGS INC | 19.62 | 38.79B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.14 | 30.28B | ||
| WAT | WATERS CORP | 31.46 | 23.78B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.75 | 19.70B | ||
| ILMN | ILLUMINA INC | 28.89 | 19.36B | ||
| MEDP | MEDPACE HOLDINGS INC | 43.25 | 17.42B | ||
| TEM | TEMPUS AI INC | N/A | 13.21B | ||
| RVTY | REVVITY INC | 21 | 11.67B |
Related stock screener links
About STVN
Company Profile
Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The company is headquartered in Piombino Dese, Padova and currently employs 5,521 full-time employees. The company went IPO on 2021-07-16. The firm delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The firm operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.
Company Info
STEVANATO GROUP SPA
Piombino Dese (Pd) Via Molinella, 17
Piombino Dese PADOVA IT
CEO: Franco Moro
Employees: 5521
Phone: 390499318173
STEVANATO GROUP SPA / STVN FAQ
What does STEVANATO GROUP SPA do?
Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The company is headquartered in Piombino Dese, Padova and currently employs 5,521 full-time employees. The company went IPO on 2021-07-16. The firm delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The firm operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.
Can you provide the latest stock price for STEVANATO GROUP SPA?
The current stock price of STVN is 23.43 USD. The price increased by 4.69% in the last trading session.
Does STEVANATO GROUP SPA pay dividends?
STEVANATO GROUP SPA (STVN) has a dividend yield of 0.29%. The yearly dividend amount is currently 0.06.
What is the ChartMill technical and fundamental rating of STVN stock?
STVN has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the analyst forecast for STVN stock?
17 analysts have analysed STVN and the average price target is 29.78 USD. This implies a price increase of 27.09% is expected in the next year compared to the current price of 23.43.
What is STEVANATO GROUP SPA worth?
STEVANATO GROUP SPA (STVN) has a market capitalization of 7.10B USD. This makes STVN a Mid Cap stock.
When does STEVANATO GROUP SPA (STVN) report earnings?
STEVANATO GROUP SPA (STVN) will report earnings on 2026-03-02, after the market close.
STVN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to STVN. When comparing the yearly performance of all stocks, STVN is one of the better performing stocks in the market, outperforming 76.99% of all stocks.
STVN Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to STVN. STVN has an excellent profitability rating, but there are some minor concerns on its financial health.
STVN Financial Highlights
Over the last trailing twelve months STVN reported a non-GAAP Earnings per Share(EPS) of 0.62. The EPS increased by 14.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.72% | ||
| ROA | 5.71% | ||
| ROE | 9.6% | ||
| Debt/Equity | 0.24 |
STVN Forecast & Estimates
17 analysts have analysed STVN and the average price target is 29.78 USD. This implies a price increase of 27.09% is expected in the next year compared to the current price of 23.43.
For the next year, analysts expect an EPS growth of 11.52% and a revenue growth 6.98% for STVN